Hillevax Inc
NASDAQ:HLVX
Intrinsic Value
Hillevax Inc is a US-based company operating in Biotechnology industry. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of HLVX.
Fundamental Analysis
Balance Sheet Decomposition
Hillevax Inc
Current Assets | 310.7m |
Cash & Short-Term Investments | 303.5m |
Other Current Assets | 7.2m |
Non-Current Assets | 33.8m |
PP&E | 32.1m |
Other Non-Current Assets | 1.7m |
Current Liabilities | 29.3m |
Accounts Payable | 7.5m |
Accrued Liabilities | 21.8m |
Non-Current Liabilities | 49.6m |
Long-Term Debt | 25.2m |
Other Non-Current Liabilities | 24.4m |
Earnings Waterfall
Hillevax Inc
Revenue
|
0
USD
|
Operating Expenses
|
-133.3m
USD
|
Operating Income
|
-133.3m
USD
|
Other Expenses
|
9.8m
USD
|
Net Income
|
-123.6m
USD
|
Free Cash Flow Analysis
Hillevax Inc
What is Free Cash Flow?
HLVX Profitability Score
Profitability Due Diligence
Hillevax Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Hillevax Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
HLVX Solvency Score
Solvency Due Diligence
Hillevax Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Hillevax Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HLVX Price Targets Summary
Hillevax Inc
According to Wall Street analysts, the average 1-year price target for HLVX is 28.76 USD with a low forecast of 21.21 USD and a high forecast of 35.7 USD.
Ownership
HLVX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
HLVX Price
Hillevax Inc
Average Annual Return | -11.18% |
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -57% |
Market Capitalization | 792.7m USD |
Shares Outstanding | 48 437 000 |
Percentage of Shares Shorted | 1.42% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Hillevax Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts. The company went IPO on 2022-04-29. HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The firm's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The firm's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-214 comprises VLPs for the two major genotypes of norovirus: GI.1 and GII.4. The firm's clinical development plan is focused on infants.